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Throe of the orisina! Norv~l~ian l~cithin:¢hol~stcrol acyltrantrera~ {LCAT) d~fi¢i¢ncy famili,s haw boca inv~stijat~ for mutations inth~ ~nt 
for I,.¢ithin:chol~tcrol acyitran~crnsc by DNA s¢~uencin~l of the e=ons amplified by th~ polymera~ chain melon. A ~inil¢ T~A tmnsvention 
in ¢odon 252 in ~on 6 converting M~t(ATG) to Lyt(AAG) wa,t observed in all homo~8ot~. In spit~ of th0 id,ntie~l mutation, tl~ dium~ 
pl~notypes diffored in ~verity. "l'hlt wa~ nat refitted in th~ ~prt~,~,ion of LCAT in th, h~t,roz'yi~t~. 
Lne.ithin:cholett¢rol a~tyltrunsf, m~ (LCAT) d¢fi¢i=ney; Mutation; R~ver~ cholesterol transport 
1. INTRODUCTION 
L~cithin:cholesterol acyitransf¢rase (LCAT~ is syn- 
th~ized in the liver and transported in plasma com- 
pleted with high density lipoprotein (HDL). It partici- 
pates in the reverse transport of cholesterol from lm- 
ripheral tissues to the liver by catalyzing the estcrifica- 
lion of cholesterol. The LCAT gone consists of 6 exons 
and is located in the ¢122.1 region of chromosome 16 
spanning approx. 4,200 bp of genomic DNA [1]. The 
matur, protein consists of 416 amino acids. 
The LCAT gen, is known to be responsible for two 
heritabl, metabolic diseases, fish eye disea.~c (FED) and 
familial LCAT deficiency. FED was first discovered in 
Sweden by Carlson and Philipson [2]. The disease is 
characterized by dyslipoproteincmia and corneal opaci- 
ties. The most striking abnormality is the rcduc, d HDL 
cholesterol contem (90% reduction compared to normal 
vain,s). In th, Swedish FED patients the LCAT activity 
was about 15% of  that of  normal plasma, However, the 
percantage ofest~rified chol~sterol in plasma was found 
to be normal. Carlson etal.  reported that them wee two 
appar¢ntly different LCAT activities involved in 
cholesterol esterification, one using HDL cholesterol as 
a sabstrate (o~-LCAT activity) and anoth,r using LDL 
and VLDL (low and very low density lipoprotcin, re- 
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Abbreviation: FED, fish ¢y¢ di~.ara; HDL. high d¢nsity lipoprot¢in; 
LCATo Iccithin:chol~t~rol acy trantff, raso; LDL. law d~nshy ilpopro- 
rein; pB.q, phosphat,-buffcred salin,; P,T. room tam~mtur¢. VLDL. 
very low density lipoprot~in. 
S1:Z~tiveiy) cholesterol as substrates ~-LCAT activity) 
[3-5]. From this FED is characterized as an a-LCAT 
deficiency. We have re~ntly sexlucnced the LCAT gone 
from two of the original Swedish FED patients and 
found that they have a mutation in ~don I0 causing the 
conversion of Pro '° (CCG) to Lau (CTG) [6]. 
Familial LCAT dmn¢ien,.-'y was discovered by Norum 
and Gjone in t967 [7]. To date more than 50 patients 
have b~n idQntified from approx. 30 families sprmd all 
over the world [8]. The mode of inheritanc~ is au- 
tosomal recessive. The phenotypic expression of the dis- 
ease varies widely and the clinical symptoms include 
renal failure, proteinuria, anemia, corneal opacity, lipo. 
protein abnormalities, premature atheros~lerosis, re- 
duced levels of plasma cholesterol esters and high levels 
of plasma cholesterol and lecithin. The LEAT activity 
in plasma is absent or extremely low in these patients 
and immunological studies have revealed that the 
LCAT protein mass is 0-60% of the normal values [9]. 
The LCAT genes from several patients have Ix:on 
studied and altogether 13 mutations have been reported 
(J. Albers, [mrsonal communication). We report her~ 
the mutation in patients from thr~ of the four Norw¢. 
gian families. Among these is the first family described 
by Norse  and Gjone [7]. All three families originate 
from the same rather isolated area. They have teen 
traced back five to seven generations and no link Im- 
tween .'hem has b,cn found [I0]. As previously reported 
[7, I 1,12] these patients have the same laboratory pheno- 
type (no detectable LCAT activity and the LCAT mass 
is 10-25% of control value), but rather variable'cl[nicai 
p~ ,~.r~ with re~rd  to ~veri,y: It w~ t hertfore of  in. 
tot,st to determine if they carried one or .~veral differ- 
=nt mutations. 
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2. MATERIALS AND METHODS 
2.1, Subj¢¢t:t 
Family 1, A female patient (M,R,} and her h;tlf-sis,er (K,R,) from 
th~ father',, tlrst marriail¢, 
Family 3, A female patient (D,J,) and her daughter (G,E.) 
Family 4, A female patient (E,R.) and her mother (M.L}, father 
(AJ.). sister (M.F3 and son iT, R3. 
Clinical and laboratory findiniP of all the paticnls ~nd their relatives 
have bccn described ¢l~where [?,l I.tZ], Alb=rs et al. have previously 
reported the LCAT activity and the LCAT mass for all the subj=ts 
cxr.cpt G,E, and T.R, [13], Blood ~mpie=¢ were drawn into EDTA- 
containing Vacutaincrs and processed witltin 20 h, 
"~ "~ DNA 
Oenomic DNA was extracted from blood =ampl~ by u~[n8 an At}I 
340A nucleic acid extractor, The ¢~lis were lysed in 9 volumes of lysis 
buffer (032 M sucrose, IO mM Tris.HCI pH 7.6. S mM MIICi;. l '~ 
Triton X.100) on i~  for $ rain. Nuclei and c¢11 debris ~=r¢ pelleted 
at I,S00 x.¢ for | $ rain. The, ~llet was war, bed in 5 ml PBS, centrifuged 
at I..~00 x t for !0 rain and r~usi~nded in PBS bel'ore loadin8 on the 
extractor. As controls DNA ~mmpl=s from l0 healthy individual,, were 
~mquenced. 
2.3. dmplO'ieal~m~ #f g¢.~,ic DNA 
Primers ( 19-2~ bases) for PCR am plilk.at ion we~ synthesizcd (Fi~. 
l) u,`in I a [k~kman System 200A DNA S)'nth~izcr. The amplilieation 
w'~ carried out in 100 ,ul usinll 0,tl-I #11 l~nomic DNA. 2,S U Taq 
polymerase (Premed), 0.2 mM dNTP and I/aM of~eh primer in a 
buffer provided wi,h the enzyme (SO mM KCI. 10 mM Tri,,-HCI pH 
9.0, I.~ mM M$Ci;, O.Ot ~f, 8elatin, 0. l~, Triton X. 100}. Initial denata. 
ration at 96"C was followed by 26cycles of 96"C (2 rain). $6"C (~- rain} 
and ~*C (3 rain). The products were purified by ¢l=trophoresis in 
1..=,-.2% apro=. The DNA was clccttophorsrmd on to DEAE mem- 
branes (NA4$, .~:hlei~l¢r and Schucll), The n'~nlbr"an~ w~re twa,hed 
in SO mM LiCI for S rain at RT and DNA ts~s elated from the 
membrane into 1.5 M LiCI at 6S*C in 4.$ rain, The DNA wasextrac[~ 
oae~ with ~lenOi/cldorofonn and ethanol precipitated, Altern~tivdy, 
the DNA wn,` ex=is~l from the 8el and centrifuged through Whatman 
3MM [t,q. 
2,4. Ser~t~e.d,~lt . f  rk¢ PCR products 
The scqu©ncin8 primers were identical to the primers used for PeR, 
Manual sequencing by the dideoxy method was d.m¢ usinl= the S¢. 
qu©nas¢ kit (USB) with the following modification: DNA (0,25 pmol) 
was denatured in a total volume of 20/JI by addin~ NaOH to a 0.2 
M final concentration. After S rain ut RT. DNA ~ts pr=:ipitat=d b), 
addin$ :5/el ?,$ M ammonium acetate and ?S/el ethanol. The DNA 
was di,olved in Scqacna= buffer and primer (20 pmol) was added. 
1"/polymerase (Pharmaeia) was used. Throughout all r~ctions NP.40 
wa,` prc=¢nt at a final concert,ration of 0.$~. 
2.5. LCAT ~trtirio" 
LCAT activi,y in plasma was m~,`ured by a method using prote- 
olipo~m~ containing apolipopro,ein A.I (Sigma) (apo-A.l:lcci- 
thin:choiesh.tol. 0,8:250:12,5 (molar atio)) ,is sub,`trate, The s-bstralc 
was preincubatcd Ibr 20 rain with human serum albumin (Sigma)(linal 
concentration 0Ji%), Plulma and mercaptoethunol (final concentra- 
tion 5 raM) were added, the mixture wa,, incubated for 60 rain at 37"C 
mtd the enzyme activity was assay~ by m~asurinp. ,he conversion of 
¢holestcrol to cholesterol ester after separation by thin.layer chromo. 
tolraphy [I S]. 
3. RESULTS 
3. I..4mM~'c~tiun and seque.chtg 
We have previously shown by Southern blotting anat- 
ysis of generate DNA from the Norwegian patients that 
no major insertions or deletions in their LCAT gent 
existed [16]. We were therefore looking for minor 
changes, singl0 base mutation or small deletion~inser- 
lions, The PCR primers (Fig. l), izav¢ different, combi- 
nations of fragments. Sequencing of all six exerts and 
parts of int~ons revealed only a single A->T transver. 
~ion in codon 252 in exon 6 causing a missense mutation 
converting Met(ATG) to Lys(AAG) (Fig, 2), The se. 
quencing ladder showed only a single band in this post. 
tion (A) indicating that the patients are homozygous for 
the mutation, The half-sister (K,R.) of the patient from 
family 1 (M,R.), did not have the mutation and the 
daughter (G,E,) of the patient from family 3 (D,J,) was 
a heterozygotc, having two bands in this position 
(A÷T), From family 4 we sequenced DNA from the 
parents of the patient (MJ, and A,J.). her son CT.R.) 
and her sister (M,F,), They were all heterozygous for the 
mutation, hav;:~g two bands in the sequencing ladder 
(A+T) (data not shown). 
3.2, LCA T activtty 
Albers et al, [13] have previously reported the LCAT 
activity for all out subjects er, cept for G,E, and T.R,, We 
have repeated these measurements and confirm tl~eir 
results, i.e, LCAT activity was very low in the patients 
(family 1, M,R4 family 3, D.J,; family 4, E.R.), and the 
3 , ,) 
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Fig. 1. Schematic repr==¢ntation f the LCAT gene. The cxon~ are boxed and arrows above ,he exons stiow the orientation and length ofth¢ S~lucnc¢ 
readings, Oligonueieotid~ numbered l - l l  were used for PCR amplification and/or scquencin$, The ¢xons are 181 157, 115, 9~, ~5 and 597 
nucieotidcs, respectively. The amplified fragment~ were: 204 Ccxon l, prinmrs 1 and 2), 2000 (e~on l.-~xon 2, primer,, I and 4), S52 (exon 2.-oxen 
4, primers 3 and 6), 620 (cxon 3-~=xon S, primer,` 5 and 7), and 603 (exon 6, prim=r~ 8 and 11), 
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LCAT deficiency normal 
Fill, 2. Direct sequencing of PCR amplified DNA. A r~n#¢.au¢l¢otide 
~e, hange fT. *A) in cedon 252 in uton 6 of the LCAT lien= it the defect 
in the Norwelilan LCAT deficiency patients. 
heterozygotes had 44.-60% of normal values in repeated 
assays (Table l). 
In one of the three families the disease phenotype is 
less severe than in the remaining two, In families I and 
4 differences in symptoms can be explained by the pa- 
tients being of different ages, In fhmily 3. however, the 
propositus has reached the age of 77 without kidney 
failure. This does not correlate with the expression of 
LCAT in tbe hemrozygotes of the various families 
(Table I) and is most likely due to the influen~ of 
modifying enes acting through other m~hunisn~s. This 
patient with the less severe phenotype lacks the large 
molecular weight LDL which is typical of the other 
LCAT patients [l 1,17] and may thus be partially pro- 
tected. 
4. DISCUSSION 
We have seq.acnccd the LCAT gone from 3 of the 4 
Norwegian families uffering from familial LCAT defi- 
ciency. Among these is the first family ever to be de- 
scribed [7]. The patients have the same mutation but 
their clinical pictures vary in severity and in laboratory 
findings, We were therefore interested indetermining if 
Table I 
LCAT activity in plasma of h~tero, and homozygotas 
Family Subj~t Enzyme Est=rification 
.clivity 
(nmol.ml") (~, of normal) 
1-2 (normal) St2 100 
l-t (homozygot¢) 0,4 0.5 
3-2 (hetcrozygot¢) 48 60 
4-t (homo'.'y~te) 1.3 i.5 
4.2 (h~terozygot¢) 44 54 
4.4 (hetcrozy$ot¢) 35 44 
4.5 (~t~mzy. m~te) 49 60 
Plasma was incubated with prot¢olipommes at 37°C and cholesterol 
• st,r was rcparutcd from cholcgerol by thin lay,r chromatography. 
The r¢sults arc presented as % activity rdntiv¢ to normal plasma. 
they carried mort: than on~ mutation, We found that all 
the patients had the tmm¢ mutation, namely a sinBIQ 
base exchange in codon 2S2 causing a conversion of 
Met(ATG}~Lys(AAG), No other repla~ments were 
detected, The half-sister (K,R,) of the patient from fam- 
ily I (M,R,) did not have th= mutation. Assuming that 
their common father w~ heteroz'ygous forthe re.oration 
and the half-sister's mother was not, the chan~ for her 
to inh,rit the mutation is only 25%. She also has a 
normal LCAT activity. The daughter (G,E,) of the pa- 
tient from family 3 (D.$.) was found to be heterozygo.as 
for the mutation having two bands in the same position. 
A and T, This s.abj~t has a reduced (59%) LCAT activ- 
ity in plasma. This w~ also the case for the subj~ts 
tested from family 4, They were all heterozygous for the 
mutation and their LCAT aotivity was red.aced to 44-- 
60% of normal valu¢, 
Albers ¢t al. [13] suggested that the apparently 
healthy members of thetse families were obli~te 
heterozygotes. The finding of red.a~d LCAT activity in 
plasma, indicated that they had only one normal allele 
for the LCAT gone. Oar res.alts confirm this hypothesis 
and show that they really am heterozygotes by the ob- 
t~vvation of two bands at the same position in the se- 
quencing ladder. 
The mutation we report here is different from those 
previo.asly reported, The two disuse phenoty~s "associ- 
ated with deficienci~ in the LCAT gone. the classical 
LCAT deficiency and the somewhat l~s tmrious FED. 
both seem to be highly alldi¢ disorders. For classical 
LCAT deficiency altogether 14 different mutations have 
been reported, ten of these are point mutations, three 
frameshifts and one is a three-base insertion whicn 
maintains the reading.frarrm. For FED three mutations 
are known [6,18,19]. The LCAT amino acid sequence 
is highly conserved between mouse, rat and human and 
all the point mutations except one are [n fully conserved 
positions, The affected po.~itions for the homozygous 
LCAT patients are L209P [20] N228K [21]. R244G (J.J. 
Aibers. personal communication) M2931 [21,22], T321 i
[20] and the mutation reported here, M252K. For the 
compound heterozygotes the affected positions are 
A93T and RI58K [20], RI35W and u frameshift at 
¢odon 375 [20], R147W and another unknown re.oration 
[23]. In one case the dil~ptide RI40-AI41 is altered to 
RI40.-GI41-AI42 [2I], In addition two other t'ra- 
meshil't mutations have be~n found asso¢iat~ with the 
LCAT phenotype, cod©ns 10-..¢16 and eodons 120.-->~8 
(J.J. Albers, personal communication). For FED so far. 
mutations have b~n observed at PIOL [6], T[231 [18.19] 
and T347M, the latter only in a compound h~terozygot¢ 
with T123I [19]. The active site of LCAT involves ~er TM. 
Cys 3t, Cys tu and an unknown histidine residue [24,.-27]. 
N~.--'n¢,. of. t~  mttt=tio~,- ~ f~.r k..,'vowr,. ~ ,'~,:.~.~ i'amilia, t 
LCAT deficiency are located directly in the sequence 
coding for the active site residues. The nature of the 
defects in enzyme action caused by these mutations i
309 
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unclear. They may be due to an abnormality in apolipo- 
protein bindin~ or an(other) alteration in secondary 
=fracture. The first possibility is supported by the tact 
that a frameshift mutation in the gene for apolipopro- 
rein A-I causes LCAT deficiency [28]. There arc proba- 
bly separate binding sit¢s on the enzyme to=" HDL and 
LDL/VLDL particles. One miBht sugl=lest hat the N- 
terminal re~ion is involved in bindin~ HDL particles 
sin~ FED is associated with mutations in codon [0 and 
codon 123, Different or more complex structures are 
involved in interactions with LDL/VLDL particles. The 
existence of two different disease phenotyixs as well as 
the variation within familial LCAT deficiency can even. 
tually be expla.~ned by the biochemical changes caused 
by the various mutations, Aeons the Norwegian fatal. 
lies there is phenotypic variation in ~pit¢ of identical 
mutations, This clearly points to the importan~ of in- 
teraction with other genes in the determination of the 
phenotype, 
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